Organ transplantation

eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference

Retrieved on: 
Thursday, October 26, 2023
Massachusetts General Hospital, Survival, RNA, Antigen, CRISPR, Cell Transplantation, Organ dysfunction, Kidney, Cell, Pelvic floor dysfunction, Transgene, System, Organ transplantation, Risk, Congress, Complement, Gene, Endothelium, Transplant, Patient, NHP, Ischemia, Pharmaceutical industry, Dentistry, Vaccine, Nature

Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.

Key Points: 
  • Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.
  • A third presentation will share the results of a study evaluating pancreatic islets from genetically engineered porcine donors transplanted into a mouse model.
  • “We’re thrilled to share data highlighting our lead candidate for kidney transplant, EGEN-2784, as well as additional data supporting our genome engineering platform.
  • Humanized porcine donors were genetically engineered using the Yucatan miniature pig breed to carry 69 genomic edits through CRISPR/Cas 9 technology.

NATIONAL UNIVERSITY HOSPITAL LAUNCHES GLOBAL FELLOWS ALLIANCE TO FOSTER INTERNATIONAL HEALTHCARE COLLABORATION

Retrieved on: 
Thursday, October 19, 2023
Knowledge, NUH, Health care, National University Hospital, Neurology, Public key certificate, Research, Federation of State Medical Boards, Obstetrics and gynaecology, Obstetrics, Vascular surgery, Organ transplantation, Gynaecology, Nursing, Creative industries

SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- In line with its mission of being Singapore's leading university hospital, the National University Hospital (NUH) is launching its highly anticipated Global Fellows Alliance. This is a pioneering initiative that aims to open doors for clinicians to engage with one another, collaborate on innovative healthcare solutions, and contribute to the advancement of medical knowledge in the region and beyond.

Key Points: 
  • SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- In line with its mission of being Singapore's leading university hospital, the National University Hospital (NUH) is launching its highly anticipated Global Fellows Alliance.
  • On 19 October, more than 50 of these fellows are gathering back in Singapore for the official launch of the Global Fellows Alliance.
  • The Global Fellows Alliance will offer a unique blend of educational activities, professional development and networking opportunities.
  • Professor Quek Swee Chye, Chairman of the Medical Board at NUH, said: "Healthcare knows no borders and the Global Fellows Alliance is a testament to our shared commitment to strengthening healthcare excellence on a global scale.

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

Retrieved on: 
Wednesday, October 11, 2023
Infection, ASPR, Inflammation, Injury, Development, Office of Inspector General, U.S. Department of Health and Human Services, Defence Research and Development Canada, University, Organization, Therapy, Administration, Organ transplantation, FDA, Biomedical Advanced Research and Development Authority, RVV, CSE, Acute respiratory distress syndrome, Disorder, DRDC, BARDA, Administration for Strategic Preparedness and Response, HHS, Research, Pharmaceutical industry, Bucillamine

TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.

Key Points: 
  • TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.
  • Under an agreement with the University of Waterloo, formulation development is ongoing and aims to be completed by the end of December 2023.
  • The Company expects to have its novel lyophilized formulation of Bucillamine ready for clinical evaluation in 2024.
  • The Company intends to explore the novel Bucillamine formulation as a potential treatment for public health medical emergencies including, pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

Global Autotransfusion Devices Market Set to Reach US$1.15 Billion by 2023, Driven by High Bleeding Surgeries and Rising Accident Cases - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 12, 2023
Medical Devices, Health, COVID-19, Hospital, Ambulatory Surgery Center Association, Compound annual growth rate, Diabetes, Orthopedic surgery, Organ transplantation, Ageing, Growth, World Blood Donor Day, Infection, Blood, Patient, Dentistry

The global autotransfusion devices market is poised for significant growth, projected to reach a value of US$1.15 billion by 2023, with a compelling Compound Annual Growth Rate (CAGR) of 5.78%.

Key Points: 
  • The global autotransfusion devices market is poised for significant growth, projected to reach a value of US$1.15 billion by 2023, with a compelling Compound Annual Growth Rate (CAGR) of 5.78%.
  • Autotransfusion devices play a vital role in medical procedures, allowing patients to become their own blood donors by reintroducing their filtered blood, minimizing infection risks.
  • The global autotransfusion devices market is segmented into three key areas:
    Type: Categorized into Products and Accessories, with intraoperative products leading the market.
  • The global autotransfusion devices market is segmented into North America, Europe, Asia Pacific, and the rest of the world.

Paragonix Technologies, Leader in Organ Transplantation, Opens New U.S. Headquarters

Retrieved on: 
Wednesday, October 4, 2023
Health, Medical Devices, Hospitals, Surgery, Research, Science, Biotechnology, Senior, Boston, Greater Boston, Patient, Laboratory, Organ transplantation, Growth, FDA, Dentistry

Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations.

Key Points: 
  • Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations.
  • This pivotal move comes during a phase of accelerated growth for Paragonix, which has experienced remarkable development since its establishment in 2010.
  • “Paragonix was conceived with a vision to revolutionize organ transplantation through accessible, clinically-proven, and cost-effective technologies, in close collaboration with the clinical community.
  • “We are proud to facilitate this essential expansion, allowing Paragonix to develop innovative transplant solutions in a unified, dynamic environment.”
    For more information about Paragonix Technologies, please visit: https://www.paragonixtechnologies.com/ .

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Retrieved on: 
Monday, October 2, 2023
Duke University, Pediatrics, Duke University School of Medicine, Old Dominion University, National Institute of Diabetes and Digestive and Kidney Diseases, Research, Kidney, American Journal, Patient, Organ transplantation, Kidney transplantation, American Journal of Transplantation, Digestive, Plasma protein binding, Duke, Dentistry, Eledone

IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.
  • Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology.
  • Transplant recipients deserve new treatment options with better efficacy and fewer side-effects to help protect their transplanted organs,” said Dr. Kirk.
  • Dr. Kirk has helped pioneer the use of co-stimulation pathway blockade to prevent organ rejection in transplant patients.

Honor the Gift disputes CMS' claim that there is no change in Medicare coverage of blood tests for monitoring rejection in transplant patients

Retrieved on: 
Wednesday, September 27, 2023
Centers for Medicare & Medicaid Services, DNA, Gift, CMS, Honor walk, Rush University Medical Center, The Wall Street Journal, International Society for Heart and Lung Transplantation, Anxiety, Lung transplantation, Patient, Policy, International Society of Sculptors, Painters and Gravers, American Society of Transplantation, Health equity, Multimedia, Transplant, LCD, Associate, Government, George Washington University Hospital, Dialysis, Medicare, Congress, George Washington School, Medical director, Physician, Organ transplantation, Division, Democrat, Surgeon, Kidney, George Washington University School of Medicine & Health Sciences, Health, Longevity, House, Society, Macs, Biopsy, Transplant surgeon, Hospital, Pharmaceutical industry, Dentistry, MD

WASHINGTON, Sept. 27, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, along with other allied leaders across the transplant field, respond to the Centers for Medicare & Medicaid Services' (CMS) press release stating that "neither CMS nor the Medicare Administrative Contractors (MACs) have made changes that affect patients' ability to have blood tests used to monitor for organ transplantation rejection covered when ordered by their physicians in medically appropriate circumstances."  

Key Points: 
  • The Honor the Gift coalition finds this statement inaccurate and contradicted by patients and physicians nationwide.
  • The changes announced on March 2, 2023, have alarmed transplant patients and clinicians across the nation, followed by an apparent decline in physician ordering of these vital blood tests1.
  • The Honor the Gift coalition and allies dispute this assertion – this is not a "clarification" but a change in coverage policy.
  • The concerns raised by patients, clinicians, and Congress emphasize the need for continued dialogue to restore longstanding Medicare coverage.

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Retrieved on: 
Monday, September 25, 2023
Heart, Male, Tacrolimus, University, Heart failure, Clinical trial, EGFR, End organ damage, University of Maryland Medical Center, Research, Plasma protein binding, History, Thumbay Hospital, Maryland School, Transplant, MD, Patient, Risk, Organ transplantation, Immune system, University of Maryland School of Medicine, Kidney transplantation, Immunosuppression, CD40L, Pharmaceutical industry, Dentistry, Eledone massyae

IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40 antibody, was used as a cornerstone component of the chronic immunosuppressive regimen administered following the second-ever transplant of a genetically modified heart from a pig to a human. The procedure was completed on September 20th at University of Maryland Medical Center on a 58-year-old male suffering from heart failure.

Key Points: 
  • IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40 antibody, was used as a cornerstone component of the chronic immunosuppressive regimen administered following the second-ever transplant of a genetically modified heart from a pig to a human.
  • The procedure was completed on September 20th at University of Maryland Medical Center on a 58-year-old male suffering from heart failure.
  • “The historic procedure we conducted on our courageous patient brings us to a pivotal moment in the history of organ transplantation.
  • Strategies to better and more safely protect transplanted organs and thus increase how long they function represent a significant area of unmet need in organ transplantation.

NKF: NEW ORGAN PROCUREMENT TRANSPLANT LAW IS GAME-CHANGER

Retrieved on: 
Friday, September 22, 2023
Kidney failure, Legislation, Senate, Distrust, OPTN, Data collection, Robin, Transplant, Patient, NKF, Organ transplantation, National Kidney Foundation, Kidney, White, House, African Americans, Dentistry, Pharmaceutical industry

WASHINGTON, Sept. 22, 2023 /PRNewswire/ -- This is a game changer!

Key Points: 
  • Organ Procurement and Transplantation Network (OPTN) Act into law
    WASHINGTON, Sept. 22, 2023 /PRNewswire/ -- This is a game changer!
  • The National Kidney Foundation was honored to join President Biden at today's signing ceremony for the OPTN Act!
  • Organ Procurement and Transplantation Network (OPTN) Act will help improve the transplant system by promoting innovation, transparency, and accountability across the system.
  • We look forward to working with the OPTN as it implements these important reforms and to continue to strengthen our nation's organ procurement and transplantation system as we work toward kidney equity for all.

Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing

Retrieved on: 
Friday, September 22, 2023
Social Media, Search Engine Optimization, Search Engine Marketing, Blogging, Other Communications, Publishing, Public Relations, Investor Relations, Marketing, Advertising, Communications, General Health, Biotechnology, Science, Other Science, Research, Health, Gene editing, Cancer, Organ transplantation, Patient, Shen Qihan, Genome, Pharmaceutical industry

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced the successful completion of a pre-Series B financing exceeding $16 million funded by a new investor, Zhejiang Industrial Fund Co., Ltd., with participation from other existing investors.

Key Points: 
  • Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced the successful completion of a pre-Series B financing exceeding $16 million funded by a new investor, Zhejiang Industrial Fund Co., Ltd., with participation from other existing investors.
  • The combined funds from this financing round and the company's reserves will provide ample capital to support the rapid product iteration and global development of gene-edited stem cell products by Qihan in the next four years.
  • There are still many core challenges to be overcome in the Off-the-Shelf cell therapy field, but the combination of gene editing and stem cell therapy holds enormous potential to create the products serving a wide range of cancer patients.
  • We will continue leveraging Qihan's research and talent advantages, work diligently, and strive to develop Off-the-Shelf cell therapy products that provide long-term patient benefits."